E. Kevin Hrusovsky, CEO & President of Caliper Life Science. Caliper is a premier provider of cutting-edge technologies enabling researchers in the life sciences industry to create life-saving and enhancing medicines and diagnostic tests more quickly and efficiently. Caliper is aggressively innovating new technology to bridge the gap between in vitro assays and in vivo results, enabling researchers to translate those results into cures for human disease. Caliper’s portfolio of offerings includes state-of-the-art microfluidics, lab automation & liquid handling, tissue microscopy, preclinical imaging technologies, and discovery & development outsourcing solutions. For more information please visit www.caliperLS.com

1. Revolutionizing Health though a
Bioeconomy
9th Annual Community College Program Day
Kevin Hrusovsky, President,
Life Sciences & Technology
June 18th 2012
1 © © 2010PerkinElmer
2009 PerkinElmer

2. United Purpose
Innovate disruptive technologies that enable early detection, next
generation treatment and disease prevention while optimizing health at an
individual level to eradicate disease and sustain earth’s ecosystem.
2

3. Agenda
1 State of Health
2 Catalyzing a Bioeconomy
3 Disruptive Technology Enabling Personalized Health
5
3 Revolutionizing Global Health

4. Life Expectancy is Slowing
Gains are
Plateauing
First time in 200 years, children’s life expectancy is shorter than parents
4

5. Life Expectancy is Inversely Correlated w/ Energy Use
Transporting 100 People
Car Bus Bicycle
http://www.howwedrive.com/2010/06/
Source: NEJM, 2005; AHRQ, 2006; CBO, 2008; CDC, 2009
5

6. While Healthcare may be Sick, There’s a Clear Path to 130
6

7. Extending Life (77 to 84) with Today’s Medicine Double Costs
$Billions
But…
-5% consume 50
-65+ spend 4x more
7

8. A Revolution in Medicine is Needed to Extend Life Economically
$2.5M
Expand life from 77 to 100 years
with Asymptomatic Medicine ~
~
8

9. Two out of Three Adults and Kids are
Overweight
 CDC - childhood diabetes &
prediabetes has mushroomed
from 9% in ’90 to 23% in ‘08
 Costs quadrupling; $400B
(NEJM, 2005; AHRQ, 2006; CBO, 2008; CDC, 2009)
9

10. Sugar Content of Common Foods
Disney: Quit
junk food ads
Michelle Obama:
End Obesity
NYC Mayor Bloomberg:
Large Soda not a Right
10

11. Population Growth Assaulting Ecosystems - Earth is Fighting Back!
Industrial Revolution; 11:59:59 on Dec 31
1B
1800
Earth Life Humans
4.5B years old 2B years old 150,000 years old
11

12. Population Growth Assaulting Ecosystems - Earth is Fighting Back!
Industrial Revolution; 11:59:59 on Dec 31
2B
1B
1800 1930
Earth Life Humans
4.5B years old 2B years old 150,000 years old
12

13. Population Growth Assaulting Ecosystems - Earth is Fighting Back!
Industrial Revolution; 11:59:59 on Dec 31
3B
2B
1B
1800 1930 1960
Earth Life Humans
4.5B years old 2B years old 150,000 years old
13

14. Population Growth Assaulting Ecosystems - Earth is Fighting Back!
7B
Industrial Revolution; 11:59:59 on Dec 31
3B
2B
1B
1800 1930 1960 2011
Earth Life Humans
4.5B years old 2B years old 150,000 years old
14

15. Population Growth Assaulting Ecosystems - World is Fighting Back!
7B
Industrial Revolution; 11:59:59 on Dec 31
4.5B years of stored fossil fuel Greenhouse gas = 400 vs. 250ppm
3B
25k species go extinct/year 80 countries have no forest left 2B
1B
25 trucks of waste for 1 good 52k gallons of water per tree
1800 1930 1960 2011
Earth Life Humans
4.5B years old 2B years old 150,000 years old
15

16. Genotype Phenotype
codes for
25+
years ago
But Today, Environmental Factors complicate
the Phenotype
ABC ? ABC
XYZ
16

17. Environment Linked to Explosion in NCDs
Radiation
Stress
Life-Style Internal chemical
environment Exposome
Xenobiotics Reactive electrophiles
Inflammation Metals
Infections Preexisting disease Endocrine disrupters
Lipid peroxidation Immune modulators
Oxidative stress Receptor-binding proteins
Gut flora
Drugs
Epigenetics
Diet
Pollution
17
Science (2010)

18. The 69-year-old sun
exposure as a trucker.
Condition known as
photoaging is caused by the
sun's UVA rays.
18

19. Environment is Linked to Explosion of NCD Incidence
Explosion in non-communicable disease (NCD):
 Cancer kills ~8M / year will rise ~72% by 2030
 T2 diabetes affects 346M  will double by 2030
 Autism affects 1/88 kids  rose 57x in ~40y
 Upsurge in asthma, rhinitis, food allergies Epigenetics is emerging as key link
between environment & NCD
epidemic
Only 25% explained by genetics alone
Environmental factors have been implicated
19
Science (2010)

20. Global Cancer Cases Could Rise 75% by 2030
5 Most Commonly Diagnosed Cancer in 2008 (incidence per 100,000)
*Very Highly Developed Countries $$$$ Men Women
June 1, 2012
• Cancer is #1 cause of death
in high-income countries Highly Developed Countries $$$
• Cancer will be major cause
of death in every region
Moderately Developed Countries $$
$$
• Cancer will rise from 12.7M
in 2008 to 22.2M by 2030
Wealthiest are 15% of the world’s Under-Developed Countries $$
population BUT bear 40% of the
cancer burden:
+ : SCREENING
- : WESTERN LIFETYLE
20 Take Away Goes Here

21. Breast Cancer – A Global Scourge
Global Incidence of Breast Cancer: 1,384,000 women diagnosed in 2008
Find & Measure CTCs Diagnosis
Prognosis
1 in 1B Prediction of Response
Circulating Tumor Cells hold great promise !
21

22. Are We Over-Testing / Treating?
http://www.thedailybeast.com/newsweek/2011/08/14/some-medical-tests-procedures-do-more-harm-than-good.html
22

23. Many “Advances” are Actually Harmful
http://positivesideeffects.com/2011/07/09/medical-care-3rd-leading-cause-of-death/
23

24. Only 25% of Cancer Drugs Work: $1 Trillion Wasted
Dual toxicity/efficacy challenge associated with the current drug-development model
Efficacy rate with standard treatment
Depression 62%
Toxicity Challenge Schizophrenia 60%
Cardiac arrhythmias 60%
Adverse drug reactions Asthma 60%
Diabetes 57%
4th leading cause of death
Osteoporosis 48%
Annual costs of approximately US$177B Hepatitis C 47%
Alzheimer disease 30%
Cancer (all types) 25%
0% 10% 20% 30% 40% 50% 60% 70%
“If not for the great variability among individuals,
medicine might have been a science and not an art.”
Sir William Osler (1849-1919)
24

25. State of Health
Life Expectancy Declining
Cost of Healthcare Skyrocketing
Global Access Insufficient
Population Exploding
Earth Traumatized – Jeopardizing Sustainable Growth
Environmental Disease Factors are Accelerating
Many of today’s medicines are unsafe and ineffective
25

26. Emerging “Health” Market…
Healthier
Genes
Surrogate
Markers
Personalized
Proteomics Medical
SNPs Intervention
Probability
of Disease
Lifestyle
Environmental Modification
Impacts
Longer Lives
Enabling Personalized Health
26 Source: http://www.slideshare.net/jcanton/future-of-health-care-presentation

27. Agenda
1 State of Health
Disruptive Technology Enabling
2
Personalized Health
3 Catalyzing a Bioeconomy
5
27 Revolutionizing Global Health

28. Three Vectors that Enable Health
28

29. Disruptive Tools to Revolutionize Health
LIFE SCIENCES & TECHNOLOGY
INFORMATICS
GENOMIC ANALYSIS BIOTHERAPEUTICS
IMAGING & PATHOLOGY TARGETED SMALL
MOLECULE
BIOMARKERS CELLULAR SYSTEMS
Prevention
29

30. The Challenge Facing Our Customers
Reverse the Decline in Drug Discovery Productivity
$1B / 15 years
DNA, RNA Cell Small Animal Tissue Human
Protein
In Vitro In Vivo
Biomarkers
Current 99%+ attrition in Focus on Big
Need predictive enabling
pre-clinical Four - Cancer,
industry (adverse drug
tests (humanistic personalized
CVS, Stroke and
models) detection and
trends: reactions) Diabetes
therapy
30

31. The Challenge Facing Our Customers
Reverse the Decline in Drug Discovery Productivity
DNA, RNA Cell Small Animal Tissue Human
Protein
In Vitro In Vivo
31

32. Revolutionary Technology: I-I-H Bridge
Strategic Goal
Clinical sequencing
capabilities
The Issue is the Tissue
Clinical
High multiplexing
Automated tissue Dx platform
Human
Accelerate pre-clinical imaging
Translational imaging probes
DATA QUALITY
Tissue
LDT to IVD capability
Global IVD and PMA
High content assays platforms
Stem cell capabilities QSR/ Dx kit manufacturing
Small Animal
Multiplex DNA/RNA
Pre-Clinical
More from less faster better
Cell
Dx and CDx Informatics systems
Integrated informatics;
research & development to
DNA, RNA clinical trials
Protein
in vitro to in vivo to human
COST OF TESTING
32

33. Automated Microfluidic Platforms for Enabling Genomics
Integrated Next Gen Sequencing Sample Prep
Sample Prep Detection
Informatics
Next Gen
Sequencing
33

34. Innovative Biomarkers & Imaging to Enable Translational Research
Oncology
Hypoxia
Folate
Her2/Neu
Annexin Liver Toxicology
Cardiovascular Adaptation of
Integrin αvβ3 select serum
markers for in
Infectious disease Cathepsins B, L, S situ imaging
Bacteria MMPs 2, 7, 9, 13
Vascular
Neutrophil Elastase Inflammation
Cathepsin K Bone Biology
Arthritis Hydroxyapatite
Gastric Emptying Physiologic
Hypertension Renin
34
From Bench to Clinic: I-I-H Bridge

35. Traditional Pathology is “Prone to Error”
60X
90,000 Ductal Carcinoma in Multiple biomarker Circulating Tumor Cells
situ (D.C.I.S.) accumulated classification
cases misdiagnosed
Do more with less faster and 1 in 1B
more precisely
* 35
New York Times, Prone to Error: Earliest Steps to Find Cancer (2010) Improving Clinical Relevance

36. Multiplex Tumor Characterization
First application - lung cancer ALK
multiplexed
others
adeno.
squamous MET
ROS
• Shrinking Sample
• Multiple Biomarkers
• NGS
36 Synergistic Technologies Increase Clinical Accuracy

37. “Driving Medicine Below the Symptom Line”
Post Treatment
Testing
Drug / Device
Intervention
Disease Progression
Diagnosis – Symptoms Appear
Prognosis
Screening Healthy
Predisposition
Testing
Source: millennium Predictive Medicine; Start-up 2000
37
Source: http://www.slideshare.net/jcanton/future-of-health-care-presentation Three Vectors that Enable Health

38. PerkinElmer Health
Lifestyle
Diagnostics Environmental
Characteristics
Environmental
LST
Settings
Informatics
38

39. Agenda
1 State of Health
2 Disruptive Technology Enabling Personalized Health
3 Catalyzing a Bioeconomy
5
39 Revolutionizing Global Health

40. The President’s Bioeconomy Blueprint – A Roadmap for the US
In April 2012, the White House unveiled a “Bioeconomy Blueprint” to harness
innovations in biological research to address national challenges in:
Health
Food
Energy
Environment
40

41. New Fast-Growing Bio Markets
Nanotechnology Molecular Diagnostics
$1.6 Trillion (by 2015, global) $15 Billion (by 2014, global)
Food Safety
Metabolomics
(contaminants, pathogens, GMOs)
$864 Million (by 2018, global)
$4.6 Billion (by 2016, US alone)
41

42. Strategic Objectives of the Bioeconomy Blueprint
Five Strategic Objectives :
1: Support R&D investments that will provide the foundation for
the future US bioeconomy
2: Facilitate transition of bioinventions from research lab to
markets (translation)
3: Reform regulations to reduce costs & increase speed , while
protecting human & environmental health
4: Update training programs & align academic institutions
incentives with student training for national workforce needs
5: Identify & support opportunities for public-private partnerships
ULTIMATE GOAL: Generate economic growth & address societal needs
EXECUTION: Demands a skilled & innovative work force – a new generation of
42 biotechnologists

43. Bioeconomy Blueprint – Fostering the Right Workforce
The Bioeconomy Blueprint” highlights the critical roll of Community Colleges in
building American Skills:
Largest component of the Nation’s higher education system
Enroll >7.6M students
Work with businesses to create tailored programs that meet local economic needs
43

44. Bioeconomy – Fostering the Right Attitude
Accelerate Disruptive Innovation
Implementation Vision
Strategic Roadmap
Culture - Leadership
360 Market Immersion
44

45. Bioeconomy Blueprint – Fostering Public-Private Partnerships
Government – Academia – Pharma – Med Inst Collaboration
IRB re-invention
Bringing technology, discovery, and development closer to patients
45

46. Personalized Health Innovation Center of Excellence
Located in Hopkinton, Massachusetts
Fully operational in late 2012
350 jobs in Center of Excellence
Will utilize “state of the art” innovation practices
46

47. 47